Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Keros Therapeutics (KROS) Shares Outstanding (2019 - 2025)

Keros Therapeutics filings provide 7 years of Shares Outstanding readings, the most recent being $40.7 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding changed 0.29% to $40.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $40.7 million, a 0.29% change, with the full-year FY2025 number at $40.7 million, changed 0.29% from a year prior.
  • Shares Outstanding hit $40.7 million in Q4 2025 for Keros Therapeutics, roughly flat from $40.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $40.7 million in Q4 2025 to a low of $23.3 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $29.7 million (2023), compared with a mean of $31.6 million.
  • Biggest five-year swings in Shares Outstanding: surged 833.97% in 2021 and later increased 0.29% in 2025.
  • Keros Therapeutics' Shares Outstanding stood at $24.0 million in 2021, then increased by 14.88% to $27.5 million in 2022, then grew by 15.6% to $31.8 million in 2023, then increased by 27.37% to $40.6 million in 2024, then rose by 0.29% to $40.7 million in 2025.
  • The last three reported values for Shares Outstanding were $40.7 million (Q4 2025), $40.6 million (Q3 2025), and $40.6 million (Q2 2025) per Business Quant data.